Table 2.
Summary of rituximab, omalizumab, and dupilumab treatment outcomes in patients with BP.
| Treatment outcomes | Rituximab | Omalizumab | Dupilumab |
|---|---|---|---|
| Patients, n (%) | 122 (100.0) | 53 (100.0) | 36 (100.0) |
| Resolution outcomes, n (%) | |||
| Complete remission | 86 (70.5) | 36 (67.9) | 24 (66.7) |
| Partial remission | 29 (23.8) | 11 (20.8) | 7 (19.4) |
| No remission | 6 (4.9) | 6 (11.3) | 5 (13.9) |
| Deterioration | 1 (0.8) | 0 (0.0) | 0 (0.00) |
| Time to remission, months | |||
| Mean | 5.7 | 6.6 | 4.5 |
| Range | 1.0-13.0 | 0.5-15.0 | 1.0-15.0 |
| NR, n (%) | 48 (39.3) | 17 (32.1) | 11 (30.6) |
| BP recurrence, n (%) | |||
| Yes | 25 (20.5) | 3 (5.7) | 2 (5.6) |
| No | 86 (70.5) | 42 (79.2) | 26 (72.2) |
| NR | 4 (3.3) | 2 (3.8) | 3 (8.3) |
| Adverse events, n (%) | |||
| None | 73 (59.8) | 34 (64.2) | 30 (83.3) |
| Death | 11 (9.0) | 1 (1.9) | 0 (0.0) |
| Infection | 8 (6.6) | 0 (0.0) | 0 (0.0) |
| Altered mental status | 4 (3.3) | 0 (0.0) | 0 (0.0) |
| Anemia | 2 (1.6) | 0 (0.0) | 0 (0.0) |
| Tachycardia | 1 (0.8) | 0 (0.0) | 0 (0.0) |
| Compression fracture | 1 (0.8) | 0 (0.0) | 0 (0.0) |
| Prostate cancer | 1 (0.8) | 0 (0.0) | 0 (0.0) |
| Metastatic breast cancer | 1 (0.8) | 0 (0.0) | 0 (0.0) |
| Mucoepidermoid carcinoma | 1 (0.8) | 0 (0.0) | 0 (0.0) |
| Dyspnea | 1 (0.8) | 0 (0.0) | 0 (0.0) |
| Thrombocytopenia | 0 (0.0) | 1 (1.9) | 0 (0.0) |
| NR | 19 (15.6) | 17 (32.1) | 6 (16.7) |
BP, bullous pemphigoid; NR, not reported; N/A, not applicable.